Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on modern management of frailty

LIVE: Thursday 17th October 2024, 18:00-19:30 (CEST)

Frailty has a significant impact on health and wellbeing, especially in older adults. Join our experts to understand the factors that contribute to the development of frailty and find out how to manage the condition and reduce the risk of disability, dependency, and mortality.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology

27-09-2024 | Acute Kidney Injury | Review

Cardiorenal syndrome: evolving concepts and pediatric knowledge gaps

Authors: Alexander J. Kula, Deirdre Bartlett

Published in: Pediatric Nephrology

Login to get access

Abstract

Cardiorenal syndrome (CRS) refers to concomitant dysfunction of both the heart and kidneys. The pathology in CRS is bidirectional. Many individuals with kidney disease will develop cardiovascular complications. Conversely, rates of acute kidney injury and chronic kidney disease are high in cardiac patients. While our understanding of CRS has greatly increased over the past 15 years, most research has occurred in adult populations. Improving cardiorenal outcomes in children and adolescents requires increased collaboration and research that spans organ systems. The purpose of this review is to discuss key features of CRS and help bring to light future opportunities for pediatric-specific research.

Graphical Abstract

Appendix
Available only for authorised users
Literature
1.
Bansal N, Arora N, Mariuma D, Jefferson JA, O’Brien K, Shankland S (2022) Mission and 1-year outcomes of a cardiorenal subspecialty consultation service. Kidney360 3:749–751PubMedPubMedCentralCrossRef
2.
3.
4.
Cooper DS, Kwiatkowski DM, Goldstein SL, Krawczeski CD (2016) Acute kidney injury and cardiorenal syndromes in pediatric cardiac intensive care. Pediatr Crit Care Med 17:S250–S256PubMedCrossRef
5.
Pradhan SK, Adnani H, Safadi R, Yerigeri K, Nayak S, Raina R, Sinha R (2022) Cardiorenal syndrome in the pediatric population: a systematic review. Ann Pediatr Cardiol 15:493–510PubMedCrossRef
6.
Ueno K, Shiokawa N, Takahashi Y, Nakae K, Kawamura J, Imoto Y, Kawano Y (2020) Kidney disease: improving global outcomes in neonates with acute kidney injury after cardiac surgery. Clin Exp Nephrol 24:167–173PubMedCrossRef
7.
Hasson DC, Alten JA, Bertrandt RA, Zang H, Selewski DT, Reichle G, Bailly DK, Krawczeski CD, Winlaw DS, Goldstein SL, Gist KM, Smith A, Brandewie KL, Bhat PN, Diddle JW, Ghbeis M, Mah KE, Neumayr TM, Raymond TT et al (2024) Persistent acute kidney injury and fluid accumulation with outcomes after the Norwood procedure: report from NEPHRON. Pediatr Nephrol 39:1627–1637PubMedCrossRef
8.
Blinder JJ, Goldstein SL, Lee V-V, Baycroft A, Fraser CD, Nelson D, Jefferies JL (2012) Congenital heart surgery in infants: effects of acute kidney injury on outcomes. J Thorac Cardiovasc Surg 143:368–374PubMedCrossRef
9.
Girgis A, Millar J, Butt W, d’Udekem Y, Namachivayam SP (2020) Peak creatinine, cardiopulmonary bypass, and mortality after stage 1 single-ventricle reconstruction. Ann Thorac Surg 109:1488–1494PubMedCrossRef
10.
Hollander SA, Montez-Rath ME, Axelrod DM, Krawczeski CD, May LJ, Maeda K, Rosenthal DN, Sutherland SM (2016) Recovery from acute kidney injury and CKD following heart transplantation in children, adolescents, and young adults: a retrospective cohort study. Am J Kidney Dis 68:212–218PubMedCrossRef
11.
Türker M, Zeyneloglu P, Sezgin A, Pirat A, Arslan G (2013) RIFLE criteria for acute kidney dysfunction following heart transplantation: incidence and risk factors. Transplant Proc 45:3534–3537PubMedCrossRef
12.
Zappitelli M, Parikh CR, Kaufman JS, Go AS, Kimmel PL, Hsu C-y, Coca SG, Chinchilli VM, Greenberg JH, Moxey-Mims MM, Ikizler TA, Cockovski V, Dyer A-M, Devarajan P et al (2020) Acute kidney injury and risk of CKD and hypertension after pediatric cardiac surgery. Clin J Am Soc Nephrol 15:1403–1412PubMedPubMedCentralCrossRef
13.
Zafar F, Lubert Adam M, Katz David A, Hill Garick D, Opotowsky Alexander R, Alten Jeffrey A, Goldstein Stuart L, Alsaied T (2020) Long-term kidney function after the Fontan operation. J Am Coll Cardiol 76:334–341PubMedCrossRef
14.
Khuong JN, Wilson TG, Grigg LE, Bullock A, Celermajer D, Disney P, Wijesekera VA, Hornung T, Zannino D, Iyengar AJ, d’Udekem Y (2020) Fontan-associated nephropathy: predictors and outcomes. Int J Cardiol 306:73–77PubMedCrossRef
15.
Feingold B, Zheng J, Law YM, Morrow WR, Hoffman TM, Schechtman KB, Dipchand AI, Canter CE et al (2011) Risk factors for late renal dysfunction after pediatric heart transplantation: a multi-institutional study. Pediatr Transplant 15:699–705PubMedPubMedCentralCrossRef
16.
Choudhry S, Dharnidharka VR, Castleberry CD, Goss CW, Simpson KE, Schechtman KB, Canter CE (2018) End-stage renal disease after pediatric heart transplantation: a 25-year national cohort study. J Heart Lung Transplant 37:217–224CrossRef
17.
Rajagopal SK, Yarlagadda VV, Thiagarajan RR, Singh TP, Givertz MM, Almond CSD (2012) Pediatric heart failure and worsening renal function: association with outcomes after heart transplantation. J Heart Lung Transplant 31:252–258PubMedCrossRef
18.
19.
Kula AJ, Prince DK, Flynn JT, Bansal N (2021) BP in Young adults with CKD and associations with cardiovascular events and decline in kidney function. J Am Soc Nephrol 32:1200PubMedPubMedCentralCrossRef
20.
Wyld ML, De La Mata NL, Hedley J, Kim S, Kelly PJ, Webster AC (2023) Life years lost in children with kidney failure: a binational cohort study with multistate probabilities of death and life expectancy. J Am Soc Nephrol 34:1057–1068PubMedPubMedCentralCrossRef
21.
Kula AJ, Prince DK, Katz R, Bansal N (2023) Mortality burden and life-years lost across the age spectrum for adults living with CKD. Kidney360 4:615–621
22.
Kellum JA, Bellomo R, Ronco C (2008) Acute Dialysis Quality Initiative (ADQI): methodology. Int J Artif Organs 31:90–93PubMedCrossRef
23.
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R (2008) Cardiorenal syndrome. J Am Coll Cardiol 52:1527–1539PubMedCrossRef
24.
House AA (2012) Cardio-renal syndrome type 4: epidemiology, pathophysiology and treatment. Semin Nephrol 32:40–48PubMedCrossRef
25.
Soni SS, Ronco C, Pophale R, Bhansali AS, Nagarik AP, Barnela SR, Saboo SS, Raman A (2012) Cardio-renal syndrome type 5: epidemiology, pathophysiology, and treatment. Semin Nephrol 32:49–56PubMedCrossRef
26.
Jois P, Mebazaa A (2012) Cardio-renal syndrome type 2: epidemiology, pathophysiology, and treatment. Semin Nephrol 32:26–30PubMedCrossRef
27.
Chuasuwan A, Kellum JA (2012) Cardio-renal syndrome type 3: epidemiology, pathophysiology, and treatment. Semin Nephrol 32:31–39PubMedCrossRef
28.
29.
Rangaswami J, Bhalla V, Blair JEA, Chang TI, Costa S, Lentine KL, Lerma EV, Mezue K, Molitch M, Mullens W, Ronco C, Tang WHW, McCullough PA et al (2019) Cardiorenal syndrome: classification, pathophysiology, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation 139:e840–e878PubMedCrossRef
30.
31.
Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM (2006) Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 47:1987–1996PubMedCrossRef
32.
Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL (2014) Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J 35:455–469PubMedCrossRef
33.
34.
Fernandez-Fernandez B, Sarafidis P, Soler MJ, Ortiz A (2023) EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors. Clin Kidney J 16:1187–1198PubMedPubMedCentralCrossRef
35.
McCausland FR, Claggett BL, Vaduganathan M, Desai AS, Jhund P, de Boer RA, Docherty K, Fang J, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CSP, Martinez F, Saraiva JFK, McGrath MM, Shah SJ, Verma S, Langkilde AM, Petersson M, McMurray JJV, Solomon SD (2023) Dapagliflozin and kidney outcomes in patients with heart failure with mildly reduced or preserved ejection fraction: a prespecified analysis of the DELIVER randomized clinical trial. JAMA Cardiol 8:56–65CrossRef
36.
Spinar J, Spinarova L, Vitovec J (2021) EMPEROR reduced - empagliflozin in patients with heart failure and reduced ejection fraction. Vnitr Lek 67:43–47PubMedCrossRef
37.
Shamseddin MK, Parfrey PS (2009) Mechanisms of the cardiorenal syndromes. Nat Rev Nephrol 5:641–649PubMedCrossRef
38.
Verbrugge FH, Dupont M, Steels P, Grieten L, Swennen Q, Tang WH, Mullens W (2014) The kidney in congestive heart failure: ‘are natriuresis, sodium, and diuretics really the good, the bad and the ugly?’ Eur J Heart Fail 16:133–142PubMedCrossRef
39.
Hanberg JS, Sury K, Wilson FP, Brisco MA, Ahmad T, Maaten JMt, Broughton JS, Assefa M, Tang WHW, Parikh CR, Testani JM, (2016) Reduced cardiac index is not the dominant driver of renal dysfunction in heart failure. J Am Coll Cardiol 67:2199–2208PubMedPubMedCentralCrossRef
40.
Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, Young JB, Tang WHW (2009) Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 53:589–596PubMedPubMedCentralCrossRef
41.
Kula AJ, Hanberg JS, Wilson FP, Brisco MA, Bellumkonda L, Jacoby D, Coca SG, Parikh CR, Tang WHW, Testani JM (2016) Influence of titration of neurohormonal antagonists and blood pressure reduction on renal function and decongestion in decompensated heart failure. Circ Heart Fail 9:e002333–e002333PubMedCrossRef
42.
Verbrugge Frederik H, Dupont M, Steels P, Grieten L, Malbrain M, Tang WHW, Mullens W (2013) Abdominal contributions to cardiorenal dysfunction in congestive heart failure. J Am Coll Cardiol 62:485–495PubMedCrossRef
43.
Li X, Liu M, Bedja D, Thoburn C, Gabrielson K, Racusen L, Rabb H (2012) Acute renal venous obstruction is more detrimental to the kidney than arterial occlusion: implication for murine models of acute kidney injury. Am J Physio Renal Physiol 302:F519–F525CrossRef
44.
Gnanaraj JF, von Haehling S, Anker SD, Raj DS, Radhakrishnan J (2013) The relevance of congestion in the cardio-renal syndrome. Kidney Int 83:384–391CrossRef
45.
Boorsma EM, ter Maaten JM, Damman K, Dinh W, Gustafsson F, Goldsmith S, Burkhoff D, Zannad F, Udelson JE, Voors AA (2020) Congestion in heart failure: a contemporary look at physiology, diagnosis and treatment. Nat Rev Cardiol 17:641–655PubMedCrossRef
46.
Hartupee J, Mann DL (2017) Neurohormonal activation in heart failure with reduced ejection fraction. Nat Rev Cardiol 14:30–38PubMedCrossRef
47.
Rea ME, Dunlap ME (2008) Renal hemodynamics in heart failure: implications for treatment. Curr Opin Nephrol Hypertens 17:87–92PubMedCrossRef
48.
Ratnasamy C, Kinnamon DD, Lipshultz SE, Rusconi P (2008) Associations between neurohormonal and inflammatory activation and heart failure in children. Am Heart J 155:527–533PubMedCrossRef
49.
Tokuda K, Kai H, Kuwahara F, Yasukawa H, Tahara N, Kudo H, Takemiya K, Koga M, Yamamoto T, Imaizumi T (2004) Pressure-independent effects of angiotensin II on hypertensive myocardial fibrosis. Hypertension 43:499–503PubMedCrossRef
50.
Buffolo F, Tetti M, Mulatero P, Monticone S (2022) Aldosterone as a mediator of cardiovascular damage. Hypertension 79:1899–1911PubMedCrossRef
51.
Srinivasa S, Abohashem S, Walpert AR, Dunderdale CN, Iyengar S, Shen G, Jerosch-Herold M, deFilippi CR, Robbins GK, Lee H, Kwong RY, Adler GK, Tawakol A, Grinspoon SK (2024) Mineralocorticoid receptor antagonism by eplerenone and arterial inflammation in HIV: the MIRABELLA HIV study. JAMA Cardiol 9:189–194PubMedCrossRef
52.
Chou Y-H, Chu T-S, Lin S-L (2018) Role of renin-angiotensin system in acute kidney injury-chronic kidney disease transition. Nephrology 23:121–125PubMedCrossRef
53.
Cowie MR, Fisher M (2020) SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond glycaemic control. Nat Rev Cardiol 17:761–772PubMedCrossRef
54.
Lockhart EN, Carr M, Allen K, Samis J, Torchen L, Laternser C, Bian Y, Patel S (2023) Prevalence of abnormal hemoglobin A1c Values in single ventricle patients following Fontan palliation. Pediatr Cardiol 44:1083–1091PubMedCrossRef
55.
Karava V, Dotis J, Kondou A, Christoforidis A, Liakopoulos V, Tsioni K, Kollios K, Papachristou F, Printza N (2021) Association between relative fat mass, uric acid, and insulin resistance in children with chronic kidney disease. Pediatr Nephrol 36:425–434PubMedCrossRef
56.
Bansal N, Weiner D, Sarnak M (2024) Cardiovascular-kidney-metabolic health syndrome: what does the American Heart Association framework mean for nephrology? J Am Soc Nephrol 35:649–652PubMedCrossRef
57.
Hatamizadeh P, Fonarow GC, Budoff MJ, Darabian S, Kovesdy CP, Kalantar-Zadeh K (2013) Cardiorenal syndrome: pathophysiology and potential targets for clinical management. Nat Rev Nephrol 9:99–111PubMedCrossRef
58.
59.
Liu Z, Li H, Su J, Xu S, Zhu F, Ai J, Hu Z, Zhou M, Tian J, Su Z, Yang P, Nie J (2019) Numb depletion promotes Drp1-mediated mitochondrial fission and exacerbates mitochondrial fragmentation and dysfunction in acute kidney injury. Antioxid Redox Signal 30:1797–1816PubMedCrossRef
60.
61.
López B, Ravassa S, Moreno MU, José GS, Beaumont J, González A, Díez J (2021) Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nat Rev Cardiol 18:479–498PubMedCrossRef
62.
Mimura I, Nangaku M (2010) The suffocating kidney: tubulointerstitial hypoxia in end-stage renal disease. Nat Rev Nephrol 6:667–678PubMedCrossRef
63.
Mueller GC, Schlueter EL, Arndt F, Dodge-Khatami A, Weil J, Mir TS (2012) Prevalence of anemia in children with congestive heart failure due to dilated cardiomyopathy. Int J Pediatr 2012:452909PubMedPubMedCentralCrossRef
64.
Montero D, Haider T, Flammer AJ (2020) Erythropoietin response to anaemia in heart failure. Eur J Prevent Cardiol 26:7–17CrossRef
65.
Kotecha D, Ngo K, Walters JAE, Manzano L, Palazzuoli A, Flather MD (2011) Erythropoietin as a treatment of anemia in heart failure: systematic review of randomized trials. Am Heart J 161:822-831.e822PubMedCrossRef
66.
67.
Packer M (2021) Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics. Am J Kidney Dis 77:280–286PubMedCrossRef
68.
69.
70.
Martínez-Maldonado M, Gely R, Tapia E, Benabe JE (1990) Role of macula densa in diuretics-induced renin release. Hypertension 16:261–268PubMedCrossRef
71.
Mullens W, Dauw J, Martens P, Verbrugge FH, Nijst P, Meekers E, Tartaglia K, Chenot F, Moubayed S, Dierckx R, Blouard P, Troisfontaines P, Derthoo D, Smolders W, Bruckers L, Droogne W, Maaten JMT, Damman K, Lassus J et al (2022) Acetazolamide in acute decompensated heart failure with volume overload. N Engl J Med 387:1185–1195PubMedCrossRef
72.
Schulze PC, Bogoviku J, Westphal J, Aftanski P, Haertel F, Grund S, von Haehling S, Schumacher U, Möbius-Winkler S, Busch M (2022) Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF). Circulation 146:289–298PubMedCrossRef
73.
Lee CR, Watkins ML, Patterson JH, Gattis W, O’Connor CM, Gheorghiade M, Adams KF (2003) Vasopressin: a new target for the treatment of heart failure. Am Heart J 146:9–18PubMedCrossRef
74.
Felker GM, Mentz RJ, Adams KF, Cole RT, Egnaczyk GF, Patel CB, Fiuzat M, Gregory D, Wedge P, O’Connor CM, Udelson JE, Konstam MA (2015) Tolvaptan in patients hospitalized with acute heart failure. Circ Heart Fail 8:997–1005PubMedCrossRef
75.
Felker GM, Mentz RJ, Cole RT, Adams KF, Egnaczyk GF, Fiuzat M, Patel CB, Echols M, Khouri MG, Tauras JM, Gupta D, Monds P, Roberts R, O’Connor CM (2017) Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure. J Am Coll Cardiol 69:1399–1406PubMedCrossRef
76.
Ikeda S, Ohshima K, Miyazaki S, Kadota H, Shimizu H, Ogimoto A, Hamada M (2017) Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure. ESC Heart Fail 4:614–622PubMedPubMedCentralCrossRef
77.
78.
Wilson TG, d’Udekem Y, Winlaw DS, Cordina RL, Ayer J, Gentles TL, Weintraub RG, Grigg LE, Cheung M, Cain TM, Rao P, Verrall C, Plessis KD, Rice K, Iyengar AJ (2019) Creatinine-based estimation of glomerular filtration rate in patients with a Fontan circulation. Congen Heart Dis 14:454–463CrossRef
79.
Kirelik D, Fisher M, DiMaria M, Soranno DE, Gist KM (2019) Comparison of creatinine and cystatin C for estimation of glomerular filtration rate in pediatric patients after Fontan operation. Congen Heart Dis 14:760–764CrossRef
80.
Stevens LA, Schmid CH, Greene T, Li L, Beck GJ, Joffe MM, Froissart M, Kusek JW, Zhang Y, Coresh J, Levey AS (2009) Factors other than glomerular filtration rate affect serum cystatin C levels. Kidney Int 75:652–660PubMedCrossRef
81.
Chen DC, Potok OA, Rifkin D, Estrella MM (2022) Advantages, limitations, and clinical considerations in using cystatin C to estimate GFR. Kidney360 3:1807–1814CrossRef
82.
Pierce CB, Muñoz A, Ng DK, Warady BA, Furth SL, Schwartz GJ (2021) Age- and sex-dependent clinical equations to estimate glomerular filtration rates in children and young adults with chronic kidney disease. Kidney Int 99:948–956PubMedCrossRef
83.
84.
Akhter MW, Aronson D, Bitar F, Khan S, Singh H, Singh RP, Burger AJ, Elkayam U (2004) Effect of elevated admission serum creatinine and its worsening on outcome in hospitalized patients with decompensated heart failure. Am J Cardiol 94:957–960PubMedCrossRef
85.
Testani JM, Coca SG, Shannon RP, Kimmel SE, Cappola TP (2011) Influence of renal dysfunction phenotype on mortality in the setting of cardiac dysfunction: analysis of three randomized controlled trials. Eur J Heart Fail 13:1224–1230PubMedPubMedCentralCrossRef
86.
Griffin M, Rao VS, Fleming J, Raghavendra P, Turner J, Mahoney D, Wettersten N, Maisel A, Ivey-Miranda JB, Inker L, Tang WHW, Wilson FP, Testani JM (2019) Effect on survival of concurrent hemoconcentration and increase in creatinine during treatment of acute decompensated heart failure. Am J Cardiol 124:1707–1711PubMedPubMedCentralCrossRef
87.
Brisco MA, Coca SG, Chen J, Owens AT, McCauley BD, Kimmel SE, Testani JM (2013) Blood urea nitrogen/creatinine ratio identifies a high-risk but potentially reversible form of renal dysfunction in patients with decompensated heart failure. Circ Heart Fail 6:233–239PubMedPubMedCentralCrossRef
88.
Valente MAE, Voors AA, Damman K, Van Veldhuisen DJ, Massie BM, O’Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Davison B, Cleland JGF, Givertz MM, Bloomfield DM, Fiuzat M, Dittrich HC, Hillege HL (2014) Diuretic response in acute heart failure: clinical characteristics and prognostic significance. Eur Heart J 35:1284–1293PubMedCrossRef
89.
Testani JM, McCauley BD, Chen J, Shumski M, Shannon RP (2010) Worsening renal function defined as an absolute increase in serum creatinine is a biased metric for the study of cardio-renal interactions. Cardiology 116:206–212PubMedPubMedCentralCrossRef
90.
Greenberg JH, Zappitelli M, Jia Y, Thiessen-Philbrook HR, de Fontnouvelle CA, Wilson FP, Coca S, Devarajan P, Parikh CR (2018) Biomarkers of AKI progression after pediatric cardiac surgery. J Am Soc Nephrol 29:1549–1556PubMedPubMedCentralCrossRef
91.
Greenberg JH, Parikh CR (2017) Biomarkers for diagnosis and prognosis of AKI in children: one size does not fit all. Clin J Am Soc Nephrol 12:1551–1557PubMedPubMedCentralCrossRef
92.
Cavalcante CTMB, Cavalcante MB, Castello Branco KMP, Chan T, Maia ICL, Pompeu RG, de Oliveira Telles AC, Brito AKM, Libório AB (2022) Biomarkers of acute kidney injury in pediatric cardiac surgery. Pediatr Nephrol 37:61–78PubMedCrossRef
93.
Maisel AS, Wettersten N, van Veldhuisen DJ, Mueller C, Filippatos G, Nowak R, Hogan C, Kontos MC, Cannon CM, Muller GA, Birkhahn R, Clopton P, Taub P, Vilke GM, McDonald K, Mahon N, Nunez J, Briguori C, Passino C, Murray PT (2016) Neutrophil gelatinase-associated lipocalin for acute kidney injury during acute heart failure hospitalizations: the AKINESIS study. J Am Coll Cardiol 68:1420–1431PubMedCrossRef
94.
Damman K, Masson S, Hillege Hans L, Voors Adriaan A, van Veldhuisen DJ, Rossignol P, Proietti G, Barbuzzi S, Nicolosi Gian L, Tavazzi L, Maggioni Aldo P, Latini R (2013) Tubular damage and worsening renal function in chronic heart failure. JACC Heart Fail 1:417–424PubMedCrossRef
95.
Kula AJ, Prince DK, Kestenbaum BR, Li S, O’Brien KD, Bansal N (2022) Kidney tubular injury biomarkers and secretory function in acute decompensated heart failure. Kidney Med 4:100418PubMedPubMedCentralCrossRef
96.
Ahmad T, Jackson K, Rao VS, Tang WHW, Brisco-Bacik MA, Chen HH, Felker GM, Hernandez AF, O’Connor CM, Sabbisetti VS, Bonventre JV, Wilson FP, Coca SG, Testani JM (2018) Worsening renal function in patients with acute heart failure undergoing aggressive diuresis is not associated with tubular injury. Circulation 137:2016–2028PubMedPubMedCentralCrossRef
97.
Varnell CD, Goldstein SL, Devarajan P, Basu RK (2017) Impact of near real-time urine neutrophil gelatinase–associated lipocalin assessment on clinical practice. Kidney Int Rep 2:1243–1249PubMedPubMedCentralCrossRef
Metadata
Title
Cardiorenal syndrome: evolving concepts and pediatric knowledge gaps
Authors
Alexander J. Kula
Deirdre Bartlett
Publication date
27-09-2024
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-024-06517-z